NASDAQ
9.07USD
-0.15 (-1.63%)
We have scored 4 news catalysts on FibroGen, Inc. (FGEN) over the past 12 months. The biggest single-day move next to one of them came Feb 9, 2026, when FGEN closed −2.2%: “Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight”. Coverage across the window leans positive (average ticker sentiment +0.10). Most of the impact sits in short squeeze potential and sector consumer.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
36.7M
P/E
—
EPS
—
Beta
0.77
52W range
4.85-21.95
Day range
9.02–9.21
Open
9.10
Prev close
9.22
Volume
29.3K
Avg volume
33.2K
Dividend
0.00
IPO
2014-11-14
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about FibroGen, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for FGEN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block connective tissue growth factor. Pamrevlumab is undergoing Phase III clinical development for multiple conditions including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with a separate Phase III trial also underway for Duchenne muscular dystrophy. FibroGen maintains strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Established in 1993, FibroGen, Inc. operates from its headquarters in San Francisco, California.
